- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 10 - Additional Sodium Glucose Cotransporter 2 Inhibitors in the Pipeline
Two sodium glucose cotransporter 2 (SGLT-2) inhibitors (canagliflozin and dapagliflozin) have received approval from the FDA. In this segment, Peter Salgo, MD, highlights 2 additional SGLT-2 inhibitors that are currently in the drug pipeline for the treatment of type 2 diabetes mellitus (T2DM).
Jeffrey D. Dunn, PharmD, MBA; Kari Uusinarkaus, MD, FAAFP, FNLA; Dr Salgo; and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss the need for additional SGLT-2 inhibitors and consider how the availability of more treatment options will affect the costs of treating and managing T2DM.
Together, the experts conclude that as new agents continue to emerge, it will be important to assess and compare their effectiveness in specific patient populations.
Dr Handelsman adds that treatment recommendations are expected to be updated as healthcare professionals gain new insight about the use of SGLT-2 inhibitors in clinical practice.
Maria Lopes, MD, MS, hopes that as more experience is gained in matching appropriate patients to appropriate therapies, real-world use will establish the clinical value of SGLT-2 inhibitors.
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Support and Skepticism Emerge as Reactions to Robert F. Kennedy Jr’s HHS Nomination
November 15th 2024In the hours after President-elect Donald J. Trump tapped Robert F. Kennedy Jr to lead HHS, reactions came swiftly to the controversial pick who would have a large influence to shake up public health.
Read More
